SOLTF (Nxera Pharma Co) Interest Expense: $-48.6 Mil (TTM As of Mar. 2026)

What is Nxera Pharma Co Interest Expense?

Nxera Pharma Co SOLTF -5.81% 84 Interest Expense is $-48.6 Mil as of Mar. 2026. GuruFocus rates SOLTF with a GF Score™ of 84/100 and a GF Value™ of $7.80 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Nxera Pharma Co's interest expense for the three months ended in Mar. 2026 was $ -1.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-48.6 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Nxera Pharma Co's Operating Income for the three months ended in Mar. 2026 was $ -13.8 Mil. Nxera Pharma Co's Interest Expense for the three months ended in Mar. 2026 was $ -1.6 Mil. Nxera Pharma Co did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nxera Pharma Co (OTCPK:SOLTF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nxera Pharma Co's Interest Expense for the three months ended in Mar. 2026 was $-1.6 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-13.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $309.6 Mil.

Nxera Pharma Co's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Nxera Pharma Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Nxera Pharma Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Interest Expense can be seen below:

Nxera Pharma Co Interest Expense Chart

Nxera Pharma Co Annual Data

Trend

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-33.36

-5.60

-17.33

-5.09

-47.94

Nxera Pharma Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-1.67	-8.71	-1.38	-36.97	-1.57

84GF Score

Nxera Pharma Co Ltd SOLTF

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nxera Pharma Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.6 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-48.6 Mil mean?

Nxera Pharma Co (SOLTF) has a Interest Expense of $-48.6 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Nxera Pharma Co and its competitors.

Is Nxera Pharma Co's Interest Expense too high?

Nxera Pharma Co's current Interest Expense is $-48.6 Mil. Overall, Nxera Pharma Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Nxera Pharma Co's Interest Expense compare to VRTX and REGN?

Nxera Pharma Co's Interest Expense of $-48.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Interest Expense is $-48.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nxera Pharma Co stock overvalued right now?

Based on GuruFocus' analysis, Nxera Pharma Co (SOLTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.80, compared to a current price of $6.00 — trading 23.1% below its estimated fair value. The current Interest Expense is $-48.6 Mil. Nxera Pharma Co's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Nxera Pharma Co (SOLTF), the current Interest Expense is $-48.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (SOLTF) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be undervalued. The current stock price of $6.00 is trading 23.1% below its estimated GF Value™ of $7.80. GuruFocus considers Nxera Pharma Co to be Modestly Undervalued.

Key valuation signals for SOLTF:

Interest Expense: $-48.6 Mil
GF Value™: $7.80 vs. price of $6.00 (23.1% below fair value)
GF Score™: 84/100 with 7 warning signs

No single metric tells the full story. See the SOLTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nxera Pharma Co Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4588 TSE:4592 TSE:4587 TSE:219A TSE:2160 TSE:4593 TSE:4894 TSE:7774 TSE:4599 TSE:4563 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 4565:Japan

Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052

Website https://www.nxera.life

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).

84GF Score

Get the complete analysis for SOLTF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.00

Price

$7.80

GF Value

View SOLTF Analysis

See Interest Expense data for all stocks →